Skip to main content

Table 1 Baseline characteristics and univariate analysis in 5035 patients with NPC

From: Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials

Characteristic

Entire cohort no. (%)a

Univariate Cox analysis

5-year OS

5-year FFS

HR (95% CI)

P

HR (95% CI)

P

Age, years

     

< 37

1175 (23.3)

Reference

 

Reference

 

38–43

1141 (22.7)

1.30 (1.01–1.67)

0.043

1.11 (0.93–1.33)

0.247

44–51

1380 (27.4)

1.35 (1.06–1.71)

0.016

1.06 (0.89–1.27)

0.483

 ≥ 52

1339 (26.6)

2.00 (1.59–2.51)

 < 0.001

1.17 (0.98–1.39)

0.079

Gender

     

Male

3697 (73.4)

Reference

 

Reference

 

Female

1338 (26.6)

0.63 (0.57–0.84)

 < 0.001

0.74 (0.64–0.86)

 < 0.001

Histological type

     

WHO type I–II

116 (2.3)

Reference

 

Reference

 

WHO type III

4919 (97.7)

0.55 (0.37–0.80)

0.002

0.51 (0.37–0.68)

 < 0.001

T category (8th edition)

     

T1

263 (5.2)

Reference

 

Reference

 

T2

364 (7.2)

1.26 (0.80–2.00)

0.322

1.20 (0.84–1.71)

0.327

T3

3049 (60.6)

1.02 (0.70–1.48)

0.936

1.01 (0.75–1.35)

0.973

T4

1359 (27.0)

1.66 (1.13–2.44)

0.010

1.51 (1.12–2.04)

0.007

N category (8th edition)

     

N0

456 (9.1)

Reference

 

Reference

 

N1

2335 (46.4)

1.67 (1.14–2.46)

0.009

1.59 (1.19–2.11)

0.002

N2

1455 (28.9)

2.50 (1.70–3.69)

 < 0.001

2.23 (1.67–2.98)

 < 0.001

N3

789 (15.7)

3.57 (2.41–5.31)

 < 0.001

3.00 (2.22–4.03)

 < 0.001

Treatmentb

     

IC + CCRT

2420 (48.0)

–

–

–

–

IC + RT

543 (10.8)

–

–

–

–

CCRT

2072 (41.2)

–

–

–

–

IC interruption during the Spring Festival

No

2542 (85.8)

Reference

 

Reference

 

Yes

421 (14.2)

1.06 (0.81–1.38)

0.692

0.94 (0.75–1.17)

0.565

RT interruption during the Spring Festival

    

No

4473 (88.8)

Reference

 

Reference

 

Yes

562 (11.2)

1.34 (1.08–1.67)

0.009

1.22 (1.02–1.46)

0.033

EBV DNA titer, copies/mL

     

< 2000

2197 (43.6)

Reference

 

Reference

 

≥ 2000

2838 (56.4)

2.08 (1.75–2.47)

 < 0.001

2.03 (1.78–2.32)

 < 0.001

LDH, U/L

     

< 250

4651 (92.4)

Reference

 

Reference

 

≥ 250

384 (7.6)

2.07 (1.66–2.59)

 < 0.001

1.67 (1.38–2.03)

 < 0.001

CRP, mg/L

     

≤ 3.00

3387 (67.3)

Reference

 

Reference

 

> 3.00

1648 (32.7)

1.60 (1.37–1.86)

 < 0.001

1.31 (1.16–1.48)

 < 0.001

Anemia

     

No

4817 (95.7)

Reference

 

Reference

 

Yes

218 (4.3)

1.44 (1.04–2.00)

0.028

1.15 (0.87–1.53)

0.320

Family history of cancer

     

No

3788 (75.2)

Reference

 

Reference

 

Yes

1247 (24.8)

0.92 (0.77–1.11)

0.376

1.01 (0.88–1.16)

0.883

Cigarette smoking

     

No

3185 (63.3)

Reference

 

Reference

 

Yes

1850 (36.7)

1.34 (1.15–1.57)

 < 0.001

1.26 (1.12–1.42)

 < 0.001

Alcohol consumption

     

No

4330 (86.0)

Reference

 

Reference

 

Yes

705 (14.0)

1.14 (0.92–1.41)

0.230

1.07 (0.90–1.27)

0.436

Comorbidity

     

No

3936 (78.2)

Reference

 

Reference

 

Yes

1099 (21.8)

1.08 (0.90–1.30)

0.403

1.04 (0.90–1.20)

0.633

  1. NPC, nasopharyngeal carcinoma; no., number; OS, overall survival; FFS, failure-free survival; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; RT, radiotherapy; EBV, Epstein-Barr virus; LDH, lactate dehydrogenase; CRP, C-reactive protein
  2. aPercentages may not add up to 100 due to rounding up of values
  3. bAll chemoradiotherapy was based on intensity-modulated radiation therapy